Adagene Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADAG Nasdaq 2836 www.adagene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adagene Inc.

Sector Update: Health Care Stocks Lean Lower Premarket Tuesday - Jul 1st, 2025 7:27 am
Adagene announces up to $25 million strategic investment from Sanofi - Jul 1st, 2025 5:00 am
Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Jun 3rd, 2025 7:40 am
Adagene to Present at Jefferies Global Healthcare Conference 2025 - May 27th, 2025 5:30 am
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 22nd, 2025 3:05 pm
Smart Share Global And 2 Other Compelling Penny Stocks To Watch - May 7th, 2025 6:05 am
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - Apr 28th, 2025 6:00 am
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 23rd, 2025 8:05 am
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - Apr 7th, 2025 6:00 am
Adagene And 2 Other Promising Penny Stocks To Watch - Apr 2nd, 2025 11:04 am
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - Mar 24th, 2025 6:00 am
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - Mar 13th, 2025 6:00 am
Adagene to Present at Leerink’s Global Healthcare Conference 2025 - Mar 6th, 2025 6:00 am
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - Feb 27th, 2025 6:00 am
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - Jan 27th, 2025 5:00 am
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - Jan 21st, 2025 3:00 pm
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 - Jan 14th, 2025 6:00 am
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Jan 8th, 2025 7:40 am
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? - Dec 23rd, 2024 7:40 am
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Dec 6th, 2024 7:40 am